Wallington Asset Management LLC Has $3 Million Holdings in Eli Lilly and Company $LLY

Wallington Asset Management LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 11.0% in the 2nd quarter, HoldingsChannel reports. The fund owned 3,846 shares of the company’s stock after selling 473 shares during the quarter. Wallington Asset Management LLC’s holdings in Eli Lilly and Company were worth $2,998,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the stock. Successful Portfolios LLC lifted its position in Eli Lilly and Company by 2.5% during the second quarter. Successful Portfolios LLC now owns 1,301 shares of the company’s stock worth $1,014,000 after acquiring an additional 32 shares during the last quarter. Grassi Investment Management raised its position in shares of Eli Lilly and Company by 0.3% in the second quarter. Grassi Investment Management now owns 79,927 shares of the company’s stock valued at $62,305,000 after buying an additional 200 shares in the last quarter. Corundum Group Inc. raised its position in shares of Eli Lilly and Company by 55.9% in the second quarter. Corundum Group Inc. now owns 1,629 shares of the company’s stock valued at $1,270,000 after buying an additional 584 shares in the last quarter. Segment Wealth Management LLC raised its position in shares of Eli Lilly and Company by 221.7% in the second quarter. Segment Wealth Management LLC now owns 4,452 shares of the company’s stock valued at $3,470,000 after buying an additional 3,068 shares in the last quarter. Finally, Fortis Capital Advisors LLC raised its position in shares of Eli Lilly and Company by 2.1% in the second quarter. Fortis Capital Advisors LLC now owns 1,771 shares of the company’s stock valued at $1,381,000 after buying an additional 37 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Saturday, September 27th. Cantor Fitzgerald dropped their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. Morgan Stanley dropped their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday. Leerink Partnrs downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Finally, HSBC upgraded shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and lifted their price target for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $933.39.

Insider Activity

In related news, Director Jamere Jackson bought 200 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were purchased at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $840.46 on Friday. The company’s 50 day simple moving average is $734.60 and its 200 day simple moving average is $766.47. The stock has a market capitalization of $795.47 billion, a price-to-earnings ratio of 54.93, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period last year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.